Anti-inflammatory Effects of Intracoronary and Intravenous Abciximab Administration During Primary Percutaneous Coronary Intervention

• Status: Completed
• Trial end date: 2008-04-01

Summary

Intracoronary abciximab administration during primary percutaneous coronary intervention (pPCI) could offer clinical advantages over the intravenous route. The aim of this study was to assess whether abciximab administration route could influence its anti-inflammatory effects. 87 consecutive STEMI patients candidate to pPCI were randomized to receive an intracoronary or intravenous abciximab bolus. The primary endpoint was the extent of inflammation, measured by C-reactive protein (CRP), VCAM-1 and ICAM-1 levels.

• Phase: Phase 4

Details

• Lead Sponsor: Azienda Ospedaliero Universitaria Maggiore della Carita
• Treatments: Abciximab; Anti-Inflammatory Agents; Antibodies, Monoclonal; Immunoglobulin Fab Fragments